CHA Biotech has secured government backing for a 3.5-year research project to advance its cell and gene therapy platforms toward clinical development, with 31.5 billion won in funding. The company was selected for a follow-up R&D project under the 2026 K-HERO Development and Support Program, led by the Ministry of Science and ICT. It will develop and commercialize CHAMS and CHAGE, with CHAGE-201 as the lead pipeline for idiopathic pulmonary fibrosis.
CHA Biotech corporate identity / Courtesy of CHA Biotech
CHA Biotech has secured government backing for a three-and-a-half-year research project aimed at pushing its cell and gene therapy platforms toward clinical development, with 31.5 billion won ($22.7 million) in funding.
The biotechnology company said Tuesday that it was selected for a follow-up research and development project under the 2026 K-HERO Development and Support Program, led by the Ministry of Science and ICT and administered by the Korea Industrial Technology Association.
The program supports corporate research centers working on national strategic technologies, with the goal of developing core technologies and turning them into commercial products.
